Improvement of time in therapeutic range with warfarin by pharmaceutical intervention

被引:5
|
作者
Viquez-Jaikel, Alvaro [1 ,2 ]
Hall-Ramirez, Victoria [3 ]
Ramos-Esquivel, Allan [4 ]
机构
[1] Hosp San Juan Dios, Unidad Atenc Farmaceut, Caja Costarricense Seguro Social, San Jose, Costa Rica
[2] Univ Autonoma Ciencias Med, Farm Hospitalaria, San Jose, Costa Rica
[3] Univ Costa Rica, Ctr Informac Medicamentos, Escuela Farm, San Jose, Costa Rica
[4] Univ Costa Rica, Dept Farmacol, Escuela Med, POB 2060, San Jose, Costa Rica
关键词
Anticoagulants; Costa Rica; Drug monitoring; International normalized ratio; Pharmaceutical intervention; Warfarin; NORMALIZED RATIO CONTROL; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; QUALITY;
D O I
10.1007/s11096-016-0403-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Anticoagulation therapy with warfarin is highly effective for prevention and treatment of thromboembolic disorders. Nevertheless, its management is challenging especially in developing countries, where the medical access is difficult and patient education is poor. Objective To determine the effect of pharmaceutical intervention (PI) on the time in therapeutic range (TTR) of a group of anticoagulated patients from our referral center. Method A group of consecutive outpatients previously treated by usual medical care underwent PI. The intervention consisted in the identification and avoidance of food and drug interactions, the confection of medication schedule charts and education to patients regarding side effects and drug monitoring. Mean TTR before and after PI was compared through the Wilcoxon test for repeated measures. Regression analyses were performed to assess the relationship between a TTR level under 65% and potential explanatory variables. Results Mean TTR before PI was 37.4 +/- 23.5% and after PI it raised to 67.0 +/- 24.9%. Mean change in TTR was +29.5% (95% CI 14.5-44.6; p < 0.001). Before PI only 4 patients had TTR values above 65%, in contrast to 18 patients after PI. Conclusion Our findings support the efficacy of PI to improve TTR values in patients treated with warfarin.
引用
收藏
页码:41 / 44
页数:4
相关论文
共 50 条
  • [31] Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
    Williams, Brent A.
    Evans, Michael A.
    Honushefsky, Ashley M.
    Berger, Peter B.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10):
  • [32] Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin
    Beton, Osman
    Asarcikli, Lale Dinc
    Sen, Taner
    Ipek, Esra Gucuk
    Kafes, Habibe
    Yaman, Mehmet
    Efe, Tolga Han
    Kaya, Hakki
    Temizhan, Ahmet
    Yilmaz, Mehmet Birhan
    PHARMACOLOGY, 2017, 99 (1-2) : 19 - 26
  • [33] Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries
    Bonde, Anders Nissen
    Lip, Gregory Y. H.
    Kamper, Anne-Lise
    Staerk, Laila
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Olesen, Jonas Bjerring
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) : 2291 - 2299
  • [34] Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
    Singer, Daniel E.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Mahaffey, Kenneth W.
    Lokhnygina, Yuliya
    Pan, Guohua
    Halperin, Jonathan L.
    Becker, Richard C.
    Breithardt, Guenter
    Hankey, Graeme J.
    Hacke, Werner
    Nessel, Christopher C.
    Patel, Manesh R.
    Califf, Robert M.
    Fox, Keith A. A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (01): : e000067
  • [35] Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range
    Marcatto, Leiliane
    Boer, Bruno
    Sacilotto, Luciana
    Olivetti, Natalia
    Darrieux, Francisco Carlos Costa
    Scanavacca, Mauricio Ibrahim
    Pereira, Alexandre Costa
    Santos, Paulo Caleb Junior Lima
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 51 (04) : 1043 - 1049
  • [36] Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range
    Leiliane Marcatto
    Bruno Boer
    Luciana Sacilotto
    Natália Olivetti
    Francisco Carlos Costa Darrieux
    Maurício Ibrahim Scanavacca
    Alexandre Costa Pereira
    Paulo Caleb Junior Lima Santos
    Journal of Thrombosis and Thrombolysis, 2021, 51 : 1043 - 1049
  • [37] Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
    Marcatto, Leiliane Rodrigues
    Sacilotto, Luciana
    da Costa Darrieux, Francisco Carlos
    Hachul, Denise Tessariol
    Scanavacca, Mauricio Ibrahim
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    ONCOTARGET, 2016, 7 (34) : 54194 - 54199
  • [38] Efficacy and safety of apixaban compared with warfarin regarding time within the therapeutic range
    Havasi Kalman
    ORVOSI HETILAP, 2014, 155 (05) : 177 - 181
  • [39] Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry
    Turk, Ugur Onsel
    Tuncer, Esref
    Alioglu, Emin
    Yuksel, Kivanc
    Pekel, Nihat
    Ozpelit, Emre
    Vuran, Ozcan
    Tengiz, Istemihan
    CARDIOLOGY JOURNAL, 2015, 22 (05) : 567 - 575
  • [40] Analysis of factors affecting time in therapeutic range control after warfarin administration
    Kose, E.
    Arai, S.
    An, T.
    Kikkawa, A.
    Aoyama, T.
    Matsumoto, Y.
    Hayashi, H.
    PHARMAZIE, 2015, 70 (07): : 494 - 498